Jan 2026· Human Mutation· Vol 2026· 1 citation· 53 references
Medicine
TL;DR
UBTD1 expression defines distinct mutation and microenvironmental states in OC and functionally promotes malignant phenotypes, potentially through TNF/AP‐1/FOS–related signaling.
Abstract
Background The ubiquitin domain‐containing protein 1 (UBTD1) is involved in protein homeostasis and cell cycle regulation, and emerging evidence suggests its role in tumor biology. However, its function in ovarian cancer (OC) remains unclear. OC is highly lethal due to late diagnosis, metastasis, and platinum resistance. This study is aimed at investigating the role of UBTD1 in OC by integrating single‐cell transcriptomics, mutation and HRD‐related analyses, tumor microenvironment evaluation, and experimental validation. Methods We examined UBTD1 expression, prognosis, somatic mutation features, and immune microenvironment characteristics utilizing public databases, such as the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Single‐cell RNA‐seq data were analyzed using Seurat, hdWGCNA, and CopyKAT to characterize UBTD1‐associated malignant‐cell states and inferred CNV burden. Based on the median UBTD1 expression, TCGA‐OV samples were divided into high and low expression groups to compare mutation spectra, DNA repair pathway activity, stromal scores, and immune cell infiltration. Functional assays were performed in A2780 and SK‐OV‐3 cell lines following lentiviral shRNAs‐mediated UBTD1 knockdown. RNA sequencing and rescue experiments were used to explore downstream pathways. Results Integrated single‐cell and TCGA‐OV analyses revealed that UBTD1‐low tumors were enriched for genomic instability–related features, including increased inferred CNV burden and higher tumor mutation burden. By comparison, UBTD1‐high tumors showed increased stromal scores and modest enrichment of selected immune‐cell populations, including macrophages and neutrophils. Experimentally, UBTD1 was upregulated in OC and associated with poor prognosis. UBTD1 knockdown inhibited malignant phenotypes, enhanced cisplatin sensitivity, promoted apoptosis, and suppressed TNF/AP‐1/FOS–related signaling. FOS overexpression partially reversed the effects of UBTD1 silencing. Conclusions UBTD1 expression defines distinct mutation and microenvironmental states in OC and functionally promotes malignant phenotypes, potentially through TNF/AP‐1/FOS–related signaling.
The PLK1/FOXM1-associated tumor-cell state may represent a distinct molecular feature associated with proliferative activity, invasive phenotypes, and macrophage-related immune features in EC and is highlighted in potential therapeutic directions for future investigation.
Long-Wei Li, Yun-yun Xiao, Ya-Ping Wang et al.· Frontiers in Oncology· 0 citations
ABSTRACT 5‐Methylcytosine (m5C) is a vital RNA modification that regulates mRNA stability, splicing, and nuclear export. As a key m5C reader, ALYREF promotes tumorigenesis across various cancers; however, its precise role in endometrial cancer (EC) remains unknown. ALYREF expression and clinical significance in EC were...
Lin-Lin Hao, Jian Zhang, Qi Qian et al.· Advancement of science· 0 citations
It is demonstrated that CEP55 is dispensable for adult tissue homeostasis but plays a critical role in tumor progression by coordinating oncogenic signaling, extracellular matrix dynamics, and tumor–immune interactions and is highlighted as a potential therapeutic target in aggressive and immune‐resistant cancers.
Behnam Rashidieh, Yuanhao Yang, Amanda L. Bain et al.· Advancement of science· 0 citations
HIST1H4L was significantly upregulated in SCLC tumors versus normal tissues and enriched in DNA transcription-related pathways and correlated with poor patient survival; critically, high HIST1H4L expression correlated with poor patient survival.
Shi-Cheng Feng, Min Feng, Zhi-Qiang Lu et al.· Frontiers in Oncology· 0 citations
BUB1 was significantly upregulated in UCEC tumors compared with normal endometrium, associated with advanced disease stage and reduced overall survival, confirming its role as an unfavorable prognostic biomarker and therapeutic target in UCEC.
Wajahat Ali, M. A. Al Mamun, Yi-Cheng He et al.· Future Journal of Pharmaceut...· 0 citations
INTRODUCTION
SLC7A11 is part of the solute carrier family and encodes the transporter xCT. However, its functional role in renal cell carcinoma (RCC) progression and associated tumor microenvironment (TME) modulation remains poorly characterized and requires further investigation. This study aimed to explore SLC7A11 ex...
Xin-Yang Cheng, Jun Zhang, Ji-Xin Yuan et al.· Current Medicinal Chemistry· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.